Ad
related to: mesenchymal vs parenchymal lung carcinoma tumor prognosis
Search results
Results from the WOW.Com Content Network
The interaction between stromal cells and tumor cells is known to play a major role in cancer growth and progression. [1] In addition, by regulating local cytokine networks (e.g. M-CSF , [ 2 ] LIF [ 3 ] ), bone marrow stromal cells have been described to be involved in human hematopoiesis and inflammatory processes.
According to the World Health Organization, lung cancer was responsible for approximately 10 million deaths in 2020. [2] The most common cause of lung cancer is long-term exposure to tobacco smoke, and the carcinogens are typically found in cigarettes. [3] In the United States, around 80%-90% of lung cancer deaths are among cigarette smokers. [4]
The following is a list of cancer types. Cancer is a group of diseases that involve abnormal increases in the number of cells, with the potential to invade or spread to other parts of the body. [1] Not all tumors or lumps are cancerous; benign tumors are not classified as being cancer because they do not spread to other parts of the body. [1]
Lung cancer, also known as lung carcinoma, is a malignant tumor that begins in the lung. Lung cancer is caused by genetic damage to the DNA of cells in the airways, often caused by cigarette smoking or inhaling damaging chemicals. Damaged airway cells gain the ability to multiply unchecked, causing the growth of a tumor.
Symptomatic features of paraneoplastic syndrome cultivate in four ways: endocrine, neurological, mucocutaneous, and hematological.The most common presentation is a fever (release of endogenous pyrogens often related to lymphokines or tissue pyrogens), but the overall picture will often include several clinical cases observed which may specifically simulate more common benign conditions.
Small-cell lung carcinoma (SCLC) has long been divided into two clinicopathological stages, termed limited stage (LS) and extensive stage (ES). [8] The stage is generally determined by the presence or absence of metastases, whether or not the tumor appears limited to the thorax, and whether or not the entire tumor burden within the chest can feasibly be encompassed within a single radiotherapy ...
Survival outcomes for stage 4 non-small lung cancer patients treated with immunotherapy alone or combined with chemotherapy in the first line: Overall survival in non-small lung cancer patients treated with immunotherapy and/or chemotherapy in the first line for advanced or metastatic disease.
Unlike extensive-stage small cell lung cancer, limited-stage small cell lung cancer is potentially curable. [4] In limited small cell lung cancer, the median overall survival time is approximately 12–16 months, with five year survival rate of approximately 26% and long-term survival rate of approximately 4–5%. [19]
Ad
related to: mesenchymal vs parenchymal lung carcinoma tumor prognosis